EVENTS MEMBERSHIP SPONSORS OFFERS JOB VACANCIES ABOUT CONTACT
GID | Oral Surgery with Vinny Patel and Emma Beecroft | Vinod Patel | Friday 08 May 2026

Oral Surgery with Vinny Patel and Emma Beecroft | Vinod Patel | Friday 08 May 2026


Dentists

For: Dentists,

Bleeders and Non-Healers, MRONJ, TMD Guidance, Orofacial Pain & Neuropathy.

Aims
  • • Re-enforce foundation knowledge regarding medication related osteonecrosis
  • of the jaw (MRONJ)
  • • Identify the various drugs implicated in MRONJ
  • • Provide an overview of anatomy, physiology and human diseases associated with haemostasis
  • • Revisit longstanding oral anti-platelets and anti-coagulants and their management for dentistry
  • • Discuss Non-Vitamin K Oral Anticoagulants (DOACs), their physiological action & management for dentistry
Objectives
  • • Determine those patients ‘at risk’ of MRONJ
  • • Recognise a differing approach to treating patients 'at risk' or with established
  • MRONJ
  • • Propose whether implants can be used in patients 'at risk' of MRONJ
  • • Highlight the value of these drugs in oral & dental disease
  • • Understand how to manage an oral bleed
Speakers

Vinod Patel

Consultant Oral Surgeon,

Guys & St Thomas Hospital (London, UK)

Mr Patel completed his specialist training in Oral Surgery at Guys & St Thomas Hospital. He successfully gained his CCST and specialist registration on the Oral Surgery list in 2014 and appointed as a consultant in 2016.

Mr Patel has a number of specialist areas. He has concentrated his service and research towards the oral and dental management of oncology patients. This includes those treated for head and neck cancer with radiotherapy as well as those given medications such as bisphosphonates, denosumab and a host of other cancer drugs implicated in osteonecrosis of the jaw. His particular interest is in osteonecrosis of the jaw and leads a tertiary service having managed over 1000 established cases of osteonecrosis of the jaw. In addition he has devised protocols to prevent osteonecrosis of the jaw reducing the risk to <1% in all cases.

Mr Patel also has a specialist interest in the conservative surgical and medical management of benign tumours and rare diseases of the jaw. He is chair of the odontogenic and rare diseases of the jaw forum where cases nationally are presented to allow for guidance and support from peers.

Mr Patel has over 175 publications in peer-reviewed journals and has presented his work at national and international conferences. He continues to be an active researcher with regards to osteonecrosis of the jaw and has grant funding as an investigator in excess of £9M. He has also served as a representative on a number of national dental committees including as a board member for the Faculty of Dental Surgery, Royal College of Surgeons England.

Sessions

09:30 - 11:00, session 1

11:30 - 13:00, session 2

14:00 - 15:15, session 3

15:45 - 17:00, session 4

GDC outcomes

A, C, D,

_MJfx6nEiYNBLwJclih5M